Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression

被引:204
作者
Katz, MM
Tekell, JL
Bowden, CL
Brannan, S
Houston, JP
Berman, N
Frazer, A
机构
[1] Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78284 USA
[2] Univ Texas, Hlth Sci Ctr, Dept Psychiat, San Antonio, TX 78284 USA
[3] Univ Texas, SW Med Ctr, Dallas VA Med CTr, Dept Psychiat, Dallas, TX USA
[4] Cyberonics, Houston, TX USA
[5] Eli Lilly & Co, Indianapolis, IN 46285 USA
[6] Harbor UCLA Med Ctr, Torrance, CA 90509 USA
[7] S Texas Vet Hlth Care Syst, San Antonio, TX USA
关键词
onset of antidepressant effects; antidepressants; desipramine; paroxetine; unipolar depression; norepinephrine; serotonin;
D O I
10.1038/sj.npp.1300341
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
This study was aimed at resolving the time course of clinical action of antidepressants (ADs) and the type of early behavioral changes that precede recovery in treatment-responsive depressed patients. The first goal was to identify, during the first 2 weeks of treatment, the onset of clinical actions of the selective serotonin reuptake inhibitor (SSRI), paroxetine, and the selective noradrenergic reuptake inhibitor, desipramine (DMI). The second aim was to test the hypothesis that the two pharmacologic subtypes would induce different early behavioral changes in treatment-responsive patients. The design was a randomized, parallel group, placebo-controlled, double-blind study for 6 weeks of treatment following a 1-week washout period. The study utilized measures of the major behavioral components of the depressive disorder as well as overall severity. The results indicated that the onset of clinical actions of DMI ranged from 3 to 13 days, averaged 13 days for paroxetine, and was 16-42 days for placebo. Furthermore, as hypothesized, the different types of ADs initially impacted different behavioral aspects of the disorder. After I week of treatment, DMI produced greater reductions in motor retardation and depressed mood than did paroxetine and placebo, and this difference persisted at the second week of treatment. Early improvement in depressed mood-motor retardation differentiated patients who responded to DMI after 6 weeks of treatment from those that did not. Paroxetine initially reduced anxiety more in responders than in nonresponders, and by the second week, significantly improved depressed mood and distressed expression in responders to a greater extent. Depressed patients who responded to placebo showed no consistent early pattern of behavior improvement. Early drug-specific behavioral changes were highly predictive of ultimate clinical response to the different ADs, results that could eventually be applied directly to clinical practice.
引用
收藏
页码:566 / 579
页数:14
相关论文
共 70 条
[1]  
ANGST J, 1970, TOFRANIL, P36
[2]  
[Anonymous], INSTRUCTION MANUAL S
[3]   Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists [J].
Artigas, F ;
Romero, L ;
deMontigny, C ;
Blier, P .
TRENDS IN NEUROSCIENCES, 1996, 19 (09) :378-383
[4]  
ASTONJONES G, 1991, J NEUROSCI, V11, P760
[5]  
BERRIDGE CW, 1991, J NEUROSCI, V11, P3135
[6]   Involvement of serotonin and dopamine in the mechanism of action of novel antidepressant drugs: A review [J].
Bonhomme, N ;
Esposito, E .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1998, 18 (06) :447-454
[7]  
Bourin M, 2001, CNS DRUG REV, V7, P25
[8]  
BOYER WF, 1994, DEPRESSION, V2, P32
[9]  
BRILEY M, 1991, HYDROXYTRYPTAMINE PS
[10]   AN INVENTORY FOR ASSESSING DIFFERENT KINDS OF HOSTILITY [J].
BUSS, AH ;
DURKEE, A .
JOURNAL OF CONSULTING PSYCHOLOGY, 1957, 21 (04) :343-349